NasdaqCM:SLSBiotechs
SELLAS Nears Key AML Data As Dual Trials Shape High-Risk Outlook
SELLAS Life Sciences Group (NasdaqCM:SLS) is nearing the pivotal Phase 3 data readout for galinpepimut-S in the REGAL trial for acute myeloid leukemia (AML).
The company has also initiated a Phase 2 trial of its CDK9 inhibitor SLS009 in newly diagnosed, high-risk AML patients.
These clinical milestones mark a key moment for the company’s AML program and broader oncology pipeline.
SELLAS Life Sciences Group focuses on late-stage, oncology-focused drug candidates, with galinpepimut-S and...